Cgp 19984
Code | Size | Price |
---|
TAR-T30817-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30817-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
CGP 19984 is a thiazolidinedione derivative that inhibits luteinizing hormone secretion and has anti-tumor effects.
CAS:
87958-64-3
Molecular Weight:
444.4
Purity:
0.98
SMILES:
O=P(OC)([O-])O[C@@H]1C(N(C)/C(S1)=N\N=C2S[C@H](C)C(N/2CC(C)=C)=O)=O.[Na+]
References
Shea WK, Black J, Ip MM. Short-term primary culture of rat prostate tumor epithelial cells on reconstituted basement membrane as a useful in vitro model to assess drug action on prostatic cancer: efficacy of the thiazolidinedione derivative CGP 19984. Prostate. 1989;15(2):157-70. Erratum in: Prostate 1990;16(2):185. PubMed PMID: 2798233.
Ip MM, Sylvester PW, Schenkel L. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion. Cancer Res. 1986 Apr;46(4 Pt 1):1735-40. PubMed PMID: 3948162.
Sylvester PW, Utz PJ, Ip MM. Effects of the thiazolidinedione derivative CGP 19984 on growth and endocrine function of the MtT-W10 transplantable mammosomatotropic pituitary tumor in female rats. Int J Cancer. 1988 Aug 15;42(2):289-94. PubMed PMID: 3403072.